Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Nivolumab/Brentuximab Vedotin Combo Is Highly Active in Relapsed/Refractory PMBCL

June 21st 2019

Nearly three-fourths of patients with relapsed/refractory primary mediastinal large B-cell lymphoma responded to a combination of nivolumab (Opdivo) plus brentuximab vedotin (Adcetris).

Rapid Changes in Multiple Myeloma Provide a Windfall of Treatment Options

June 21st 2019

S. Vincent Rajkumar, MD, discusses the rapidly changing landscape for the treatment of multiple myeloma, the future of immunomodulatory drugs, and whether quadruplet regimens will become more frequent.

FDA Issues Complete Response Letter for Quizartinib in AML

June 21st 2019

The FDA has issued a complete response letter to Daiichi Sankyo informing the company that its new drug application would not be approved for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.

Optimal Upfront Lenalidomide/R-CHOP Use Remains Puzzle in DLBCL

June 20th 2019

Patients with activated B-cell-type diffuse large B-cell lymphoma with a poor prognosis may benefit from frontline treatment with lenalidomide plus standard R-CHOP, according to subgroup data from the phase III ROBUST trial presented at the 2019 International Conference on Malignant Lymphoma.

Dr. Davids on the Phase II CRC043 Trial for Patients With Richter's Transformation

June 19th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of the BCL‐2 inhibitor, venetoclax (Venclexta) with dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (R-EPOCH) to treat patients with Richter

Maintenance Therapy Remains Challenging Strategy in DLBCL

June 19th 2019

Maintenance therapy with rituximab did not lead to an improvement in disease-free survival among patients who achieved complete remission following 4 cycles of R-CHOP.

Quizartinib Receives Japanese Approval in Relapsed/Refractory FLT3+ AML

June 18th 2019

The Ministry of Health, Labor and Welfare of Japan has approved quizartinib for the treatment of adult patients with relapsed/refractory FTL3-ITD–positive acute myeloid leukemia, as detected by an MHLW-approved assay.

HCL Management: Recommendations and Advice

June 18th 2019

Moxetumomab Pasudotox in HCL

June 18th 2019

Non-Chemotherapy Agents & Anti-CD22 in HCL Treatment

June 18th 2019

BRAF/MEK Inhibition in HCL Management

June 18th 2019

The Use of Splenectomy in HCL Treatment

June 18th 2019

Treating Relapsed/Refractory or Progressive HCL

June 18th 2019

The Role of MRD in Treatment of HCL

June 18th 2019

Concurrent vs Sequential Rituximab in HCL

June 18th 2019

HCL Combination Therapy: Rituximab and Purine Analog

June 18th 2019

Indicators Prompting Treatment of HCL

June 18th 2019

First-Line Therapy Options in Hairy Cell Leukemia

June 18th 2019

Parting Advice on Hairy Cell Leukemia Management

June 18th 2019

Hairy Cell Leukemia: Unmet Needs and Combination Strategies

June 18th 2019